Mental health company dedicated to providing access to safe and affordable psychedelic-assisted therapy, beginning with ketamine therapy.
Fully integrated, pre-clinical stage biotechnology company developing therapeutics for the accessible treatment of psychiatric diseases
MindMed discovers and develops psychedelics inspired medicines
Gilgamesh is developing the next generation of central nervous system drugs derived from psychedelics
Diamond Therapeutics develops psilocybin based medicines while mitigating side effects
Myco Systemics' mission is to provide systemic scalable myco-cultivation infrastructure to enable producers to meet the demands of the exploding global mushroom market
Tactogen is a public benefit cooperation whose goal is to make transformative medicines safer, more effective, and more accessible
Mindleap's integration coaches help you to understand and embody the most important parts of your Psychedelic trip, allowing you to create lasting personal transformation.
ATAI is committed to developing more effective and potentially disease-modifying mental health treatments by researching both psychedelic and non-psychedelic compounds.
Universal Ibogaine's mission is to bring proven Ibogaine based clinical treatment protocol to the world and help solve the international opioid crisis
GoodCap is developing effective mushroom-based treatments that open new pathways to a healthier future.
Gwella's focus is on developing transformative consumer brands, products and technologies aimed at elevating people's health and wellbeing.
Lucid News provides informed, honest and transparent journalism that covers the growing integration of psychedelics into society and their broad implications for human wellness.
.
A digital media company covering psychedelics and all they intersect with, from healthcare disparities to the climate crisis
.
A life sciences company whose mission is to treat traumatic brain injury and other mental health ailments using psilocybin and other natural therapies.
Psychedelic Therapy Software & Management.
Awakn Life Sciences is a biotechnology company with clinical operations researching, developing, and delivering psychedelic new chemical entity drugs and therapies to treat Addiction.
TRIPP is an award-winning breakthrough wellness platform.
Psilera is reimagining psychoactive natural products as building blocks for the next generation of neurological therapeutics.
September 27-29, 2024 - New York, New York
Simeon is bringing his perspective on psychedelic investment to this world-class event, which brings together today’s most inspiring changemakers, funders, and policy-makers to share their work, collaborate on impactful projects, and co-create truly transformative change.
Find more information on attending here: https://transformative.global/NYC2024
Lindsay Hoover was interviewed for this article: "LSD, Ecstasy Lure Traders Betting on ‘Psychedelic Renaissance’"
Lindsay Hoover was interviewed for this article on MAPS PBC's milestone drug application filing with the FTC.
Simeon Schnapper was interviewed by Jen Coleman, CEO of Elevated Experiences, in advance of of his speaking appearance at Khaner Global's Cannabis and Psychedelics Investment conference later this month
Simeon Schnapper was interviewed for this article on the challenges facing the rapidly expanding psychedelics industry
Simeon Schnapper is among the major psychedelics VC & EFT directors who shared valuable insights at the Psychedelics Capital Conference (PCC)
How Awkn is navigating the tough market for investment capital
Psychedelics were the hot topic at the World Economic Forum 2022
How Awkn is navigating the tough market for investment capital
How Awkn is navigating the tough market for investment capital
He was the Canadian head of the world’s largest pot company. His next big bet? A rare fungus worth thousands a kilogram
Will Psychedelics Continue To Grow In 2021? Jeff Siegel Shares Insights And Strategies As More Companies Go Public
Why Would Anyone Invest In The Psychedelics Medicine Market?
Why Investors Are Bullish About Psychedelics
Interview with Jeff Siegel, Managing Partner of JLS Fund
Ibogaine: The ‘Strange Kind of Drug’ for Transcending Addiction
Psychedelics Replace Pot as the New Favorite Edgy Investment
Why The Psychedelics Market Is NOT Cannabis 2.0
Investors are pouring millions into startups that are developing magic mushrooms as medications for conditions like depression and PTSD
Meet the top 14 psychedelics startups raising the most cash to develop new ways of treating depression, addiction, and more
Psychedelic Industry Continues To Draw Millions In Investments
Simeon spoke in this event, hosted by Psychedelics for Climate Action (PSYCA)
Simeon was featured in the Salon, "Making the Magic: In Search of Production Innovation to Meet the Challenges of the Psychedelics Supply Chain."
Simeon gave a keynote address: "African Psychedelics Can Heal The World's Trauma."
Simeon presented at this annual gathering in Boston.
JLS attended this annual community event at the New York Academy of Medicine, the longest-running of its kind in the world.
JLS attended "The Summit of Breakthrough Therapies for Addictions" in Miami, Florida.
Simeon Schnapper spoke on the online TTI Panel: Psychedelic and Mental Health VC.
Simeon Schnapper spoke on the online TTI Panel: Psychedelic and Mental Health VC.
JLS attended the Cayman Alternative Investment Summit (CAIS), which brought together leaders from multiple segments of the alternative investment world.
Lindsay Hoover moderated the "Mental & Behavioral Health Panel" at Redefining Early Stage Investments' annual in person conference.
Simeon Schnapper spoke at Kahner Global's 7th annual summit in New York City.
Lindsay Hoover and Simeon Schnapper spoke on a panel at this thought- leadership event, presented by Microdose.
Lindsay Hoover spoke at SOCAP Global's annual conference on the following panel: "Impact Investment in Psychedelics: exploring new waters in mental health impact."
Simeon Schnapper spoke on the Business Track panel at the MIND Foundation's INSIGHT Conference in Berlin.
Simeon Schnapper spoke on the panel, "The Psychedelics Business Landscape: Are Companies Faltering or Failing, And Why?"
Leonard Pickard spoke about the underground history of LSD and its "overground future" at MAPS' fourth annual conference on the future of psychedelic medicine.
Lindsay Hoover spoke on two panels at MAPS' fourth annual conference on the future of psychedelic medicine.
Simeon Schnapper co-hosted a thought provoking discussion on the intersection of psychedelics, AI, and robotics.
Simeon Schnapper spoke at the Benzinga Psychedelics Capital Conference in Miami Beach, Florida.
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at a private event
William Leonard Pickard spoke at an interdisciplinary symposium at Ohio State University on the future of psychedelic research
William Leonard Pickard spoke at the first annual "Psychedelic Science and Spirituality Summit" in Stowe, Vermont
William Leonard Pickard spoke at Horizons Northwest's "Perspectives on Psychedelics" conference
Lindsay Hoover spoke at Horizons: The Psychedelic Business Forum, the largest and longest-running annual gathering of the psychedelic community in the world
Simeon Schnapper spoke on a panel discussing the intersection of psychedelic research, treatments, and investment
Simeon Schnapper on the tensions between philanthropic and for-profit investment, and the challenges and opportunities of this explosive new sector.
Political Importance of Ibogaine Development with Rick Doblin, JLS' Simeon Schnapper, and Daniel Callahan
Simeon Schnapper and Lindsay Hoover discuss investing in the psychedelic space and the developing ecosystem of this emerging industry.
William Leonard Pickard presented at a panel entitled: The Pathway to Federal Acceptance
Lindsay Hoover speaks on Consolidation in the Psychedelics Industry: What to Expect
William Leonard Pickard and Caleb O. Brown discuss promise and pitfalls in taking psychedelic medicine mainstream.
Lindsay Hoover on differentiating opportunities between private & public companies
Jeff Siegel on investing in the future of mental healthcare: psychedelics as an asset class
Revolutionizing Healing Through Psychedelic Medicine with Simeon Schnapper
Lindsay Hoover
Simeon Schnapper in Singularity U's first ever panel on psychedelics!
Psychedelics Roundtable with Simeon Schnapper of JLS Fund
Psychedelic Philanthropy with Simeon Schnapper of JLS Fund
Simeon Schnapper moderates a panel on addressing mental health through emerging therapies.
Simeon Schnapper of JLS Fund
Lindsay Hoover of JLS Fund: Psychedelics as Therapeutics: The Contribution of Game Heuristics
Lindsay Hoover of JLS Fund
Lindsay Hoover and Simeon Schnapper, Managing Partners of JLS Fund
Understanding The Psychedelic Medicine Industry: Q&A with Kevin O'Leary and JR Rahn
Watch Simeon Schnapper on Pysched, the show that explores psychedelics through political, social, and economic perspectives.
Stay up to speed with the world of psychedelics with our weekly updates. Sign up.